{"id":"NCT03127956","sponsor":"Dermira, Inc.","briefTitle":"A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","officialTitle":"An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-21","primaryCompletion":"2018-04-27","completion":"2018-04-27","firstPosted":"2017-04-25","resultsPosted":"2019-02-05","lastUpdate":"2021-07-20"},"enrollment":748,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Olumacostat Glasaretil Gel, 5.0%","otherNames":["DRM01B"]}],"arms":[{"label":"Olumacostat Glasaretil Gel, 5.0%","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris","primaryOutcome":{"measure":"Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions","timeFrame":"Day 1 - Week 36","effectByArm":[{"arm":"Olumacostat Glasaretil Gel, 5.0%","deltaMin":197,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":94,"countries":["United States","Australia","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":741},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Application site pruritus","Application site pain","Application site dryness"]}}